Neurophet AQUA AD Plus

by Neurophet  · Based in South Korea → — Pioneer in AI-Driven Diagnosis and Treatment of Brain Disorders
Neurology Nuclear Medicine Radiology

Regulatory Status Disclosed

Overview

Neurophet AQUA AD Plus is an AI-based software solution designed to support the clinical evaluation of Alzheimer’s disease. It analyzes brain MRI and PET images to automatically identify and quantify lesions, brain structures, and atrophy. The software helps clinicians monitor potential treatment-related side effects in patients receiving anti-amyloid therapies and provides quantitative insights to facilitate informed clinical decision-making. It integrates MRI and PET analysis within a single software environment, allowing for comprehensive assessment of Alzheimer’s disease-related imaging data. The tool also supports early diagnosis and staging of Alzheimer’s disease, safe treatment management by detecting microbleeds and assessing treatment-related side effects, and long-term monitoring of disease progression and treatment efficacy.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered brain MRI analysis
  • Automated identification and quantification of hypointense lesions (cerebral microbleeds, superficial siderosis)
  • Automated identification and quantification of hyperintense lesions (brain edema)
  • Quantitative analysis of MRI and PET images
  • Automated labeling and visualization of brain structures
  • Volumetric quantification of brain structures and lesions
  • Standardized Uptake Value Ratio (SUVR) analysis for PET imaging
  • Comparison with normative reference data
  • Report generation
  • Multi-time-point analysis

Use Cases

  • Monitoring potential treatment-related side effects in Alzheimer's patients receiving anti-amyloid therapies
  • Supporting imaging-based clinical decision-making in Alzheimer's disease
  • Early diagnosis and staging of Alzheimer's disease
  • Assessing patient eligibility for Alzheimer's disease treatments
  • Evaluating treatment outcomes after administration of Alzheimer's therapies
  • Long-term monitoring of disease progression and treatment efficacy

Details

Category Neurology AI, Radiology & Imaging AI
Pricing Unknown
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Neurology, Nuclear Medicine, Radiology

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2026-01-29K252496 510(k)Neurophet AQUA AD Plus

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Neurophet AQUA AD Plus

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for Neurophet AQUA AD Plus.

Loading videos...

View all on YouTube

No FAQs available yet for this tool.

Related Tools

syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
myosmart trial kit
Otto Bock Healthcare Products GmbH
Neurology AI
The Ottobock MyoSmart Trial Kit assists clinicians in assessing and fitting advanced neurorehabilitation prosthetic and orthotic solutions.
connectgrip. (560X27-1)
Otto Bock Healthcare Products GmbH
Neurology AI
Otto Bock Healthcare Products GmbH offers advanced prosthetic and orthotic solutions, with 'connectgrip' (560X27-1) likely being a component designed for secure and functional connection within these systems, potentially incorporating intelligent features for enhanced user control.
myosmart.cuff (757M20-2)
Otto Bock Healthcare Products GmbH
Lab & Diagnostics
The myosmart.cuff is a medical device by Otto Bock Healthcare Products GmbH designed for objective measurement of muscle tone, primarily for use in neurological rehabilitation.
myosmart. (13E522)
Otto Bock Healthcare Products GmbH
Neurology AI
myosmart.
EMLA (Elekta Infintiy)
Elekta Solutions AB
Neurology AI
Elekta is a leading innovator in precision radiation therapy, driven by the core motivation to provide hope for everyone dealing with cancer. They develop and produce radiation therapy and radiosurgery-related equipment and clinical management for the treatment of cancer and brain disorders.

See all Neurology AI tools →

More in the Neurophet AQUA line

Neurophet AQUA Neurophet AQUA AD Plus (this page)

More from Neurophet

Neurophet AQUA
Neurophet
Neurology AI
AI-powered software for quantitative analysis of brain MRI and PET images, assisting clinicians in the diagnosis, treatment, and monitoring of neurodegenerative diseases like Alzheimer's and Multiple Sclerosis.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-20 | First Added: 2026-11-20
AI Tool Finder
AI-powered search. Results may not be comprehensive.